Moderna & Merck’s mRNA Cancer Vaccine Secures EMA PRIME Designation

Apr 12 2023

• By Neena Brizmohun

Listen to this article

A total of four investigational products targeting unmet medical needs have made it onto the European Medicines Agency’s priority medicines scheme so far this year.

Thumbs up — New applications for entry onto the PRIME scheme get the thumbs up • Source: Shutterstock

Moderna, Inc. and Merck & Co., Inc.'s* investigational personalized mRNA cancer vaccine, mRNA-4157/V940, has secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme, for use in combination with Merck’s Keytruda (pembrolizumab) for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.

The PRIME designation for the therapy “highlights the potential promise of individualized cancer treatments in a population with limited alternatives,"...

More from Review Pathways

PS-Pathways&Standards (Free-1): Industrial Chemicals Within Us - The Ubiquity of Industrial Products in the Human Body
Jun 14 2025
• By Nabil
Exploring How Everyday Industrial Compounds Enter Our Systems, Their Health Implications, and the Ongoing Quest for Safer Alternatives .
Brazil Issues Guidance On Regulatory Reliance & Equivalent Authorities
Oct 02 2024
• By Francesca Bruce
Brazilian regulator Anvisa is relying on the decisions of its foreign counterparts as a means of ensuring more quality medicines are made available in the country.
Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva
Sep 30 2024
• By Sue Sutter
The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.
UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures
Sep 25 2024
• By Ian Schofield
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.

More from Pathways & Standards

Anvisa To Access US FDA-Reviewed Data For More Robust Evaluations In Brazil
Oct 02 2024
• By Francesca Bruce
Brazil has also published its recent regulatory reliance regulations in English, a move designed to increase confidence in its decisions as it presses on with aligning its national practices with global best practices.
Califf: Rare Disease Hub Will Develop Methods To Guide Approvability Determinations
Sep 30 2024
• By Sarah Karlin-Smith
The US FDA commissioner also said the hub is looking for an executive director who will work with the CBER and CDER heads, who will serve as co-leads.
Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva
Sep 30 2024
• By Sue Sutter
The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.